Endocrine Abstracts

Introduction: Childhood obesity remains a major health concern and there are a number of serious complications associated with it. These include type 2 diabetes mellitus (T2DM), obstructive sleep apnoea (OSA), idiopathic intracranial hypertension (IIH) and non-alcoholic fatty liver disease (NAFLD). Glucagon-like peptide 1 (GLP-1) therapy has shown promising results for weight loss in adults and has recently been approved for the use in the treatment of childhood obesity for ad...

Introduction: The prevalence of childhood obesity is continuing to increase, especially in more deprived areas. It is estimated that 28% of children are overweight or obese in England. Evidence has shown that obesity is associated with increased intracranial pressure (ICP) in adult and paediatric populations. We report three patients who presented with intracranial hypertension due to severe obesity.Case 1: A fifteen-year-old girl presented with severe h...

Background and aims: A critical component of adrenal insufficiency (AI) management is education for the family and young person regarding sick day episode management. Deficits in patient education have been identified to contribute to adrenal crisis risk. The aim of this online survey distributed via the British Society for Paediatric Endocrinology (BSPED) paediatric endocrine nurse specialists (PENS) mailing list is to identify current clinical practice regarding education in...

Introduction: Long-acting growth hormone (LaGH) therapy has emerged as a newer treatment option for children, with the potential to improve adherence and compliance. Clinical trials have shown LaGH formulations to be effective and safe in children with GH deficiency (GHD). Somatrogon (Ngenla) is licensed for use in children with GHD over than 3 years of age.Objective: We report the real-world experience of using once wee...

Introduction: Delayed detection of short stature can lead to missed opportunities to optimise adult height and failure to diagnose important underlying pathologies. We speculated that children from more deprived communities may be less likely to be diagnosed with growth hormone (GH) deficiency, and that growth outcomes may be poorer in children treated with GH from deprived communities, in light of outcome data from other chronic childhood conditions. We compared the demograph...

Background: Pubertal progression is inhibited in central precocious puberty with the use of gonadotropin releasing hormone (GnRH) analogues. They are usually given every 10 to 12 weeks via an intramuscular depot, but more recently, a 6-monthly preparation has become available for clinical use.Aim: The aim of this project was to evaluate the efficacy and acceptability of 6-monthly triptorelin, a GnRH analogue, at a tertiary children’s hospital.<p...